BBLG VS ONCS Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price Targets
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price Targets

Performance

BBLG
10/100

BBLG returned -94.35% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

ONCS
10/100

ONCS returned -98.65% in the last 12 months. Based on SPY's performance of -6.50%, its performance is below average giving it a score of 10 of 100.

Technicals

BBLG
14/100

BBLG receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

ONCS
25/100

ONCS receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Earnings

BBLG
49/100

BBLG has missed earnings 2 times in the last 20 quarters.

ONCS
10/100

ONCS has missed earnings 8 times in the last 20 quarters.

Profit

BBLG
10/100

Out of the last 20 quarters, BBLG has had 1 profitable quarters and has increased their profits year over year on 1 of them.

ONCS
10/100

Out of the last 20 quarters, ONCS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BBLG
46/100

BBLG has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

ONCS
57/100

ONCS has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

Analyst Price Targets

BBLG

"Analyst Price Targets" not found for BBLG

ONCS
75/100

4 analysts offer 12-month price targets for ONCS. Together, they have an average target of 0, the most optimistic target put ONCS at 0 within 12-months and the most pessimistic has ONCS at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

All score calculations are broken down here to help you make more informed investing decisions

Bone Biologics Corp Common Stock Summary

Nasdaq / BBLG
Healthcare
Medical - Devices
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

OncoSec Medical Incorporated Summary

Nasdaq / ONCS
Healthcare
Biotechnology
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.